Keryx Biopharmaceuticals, Inc. Announces Poster Presentations,Highlighting Mechanism of Action and Clinical Activity of,Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American,Diabetes Association 67th Scientific Sessions in Chicago, Illinois
the doses used for suchindications. Additionally it has been demons...ABOUT KERYX BIOPHARMACEUTICALS INC. ...Keryx Biopharmaceuticals Inc. is focused on the acquisitiondevelopm...
the doses used for such
indications. Additionally, it has been demonstrated in multiple
clinical trials conducted in Europe and the U.S., including two
randomized, double-blind, placebo-controlled Phase II studies, that
Sulonex can reduce urinary protein excretion in patients with
diabetic nephropathy. Sulonex is in a pivotal Phase III and Phase
IV clinical program under a Special Protocol Assessment, or SPA,
with the Food & Drug Administration, or FDA. These trials are
being conducted by the Collaborative Study Group, or the CSG, the
world's largest standing renal clinical trials group.
ABOUT KERYX BIOPHARMACEUTICALS, INC.
Keryx Biopharmaceuticals, Inc. is focused on the acquisition,
development and commercialization of medically important, novel
pharmaceutical products for the treatment of life-threatening
diseases, including diabetes and cancer. Keryx's lead compound
under development is Sulonex(TM) (sulodexide oral gelcap),
previously referred to as KRX-101, a first-in-class, oral
heparinoid compound for the treatment of diabetic nephropathy, a
life-threatening kidney disease caused by diabetes. Sulonex is in a
pivotal Phase III and Phase IV clinical program under a Special
Protocol Assessment with the Food & Drug Administration.
Additionally, Keryx is developing Zerenex(TM), an oral, inorganic,
iron-based compound that has the capacity to bind phosphate and
form non-absorbable complexes. Zerenex is currently in Phase II
clinical development for the treatment of hyperphosphatemia
(elevated serum phosphorous levels) in patients with end- stage
renal disease. Keryx is also developing clinical-stage oncology
compounds, including KRX-0401, a novel, first-in- class, oral
modulator of Akt, a pathway associated with tumor survival and
growth, and other important signal transduction pathways. KRX-0401
is currently in Phase II clinical development for multiple tumor
types. Keryx also has an active in-licensing and acquisition
program designed to id
'"/>
Page: 1 2 3 4 Related medicine technology :1.
Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase
II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple
Myeloma and Waldenstroms Macroglobulinemia2.
AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results
for Anti-Cancer Compound Perifosine at ASCO Meeting3.
Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial4.
Neose Announces Presentation of Positive Preclinical Data on
GlycoPEGylated Factor VIIa at the XXI Congress of the International
Society on Thrombosis and Haemostasis5.
Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy
of BF-200 ALA In Actinic Keratosis6.
YM BioSciences Announces Secondary Efficacy and Safety Findings in
Randomized Phase IIB Aerolef Trial7.
BioSante Pharmaceuticals Announces New Findings for Potential Bird
Flu Vaccine8.
Portola Pharmaceuticals Announces Positive Data from a Phase II
Study of its Factor Xa Inhibitor at the XXI Congress of the
International Society on Thrombosis and Haemostasis9.
Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for
Oral Oleoyl-estrone10.
AVI BioPharma Partner Cook Medical Announces Completion of Patient
Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of
Cardiovascular Disease11.
Protox Announces Positive Clinical Data from Prostate Cancer Study
... Associations Collaborate to Improve Patient Safety, ... of,Cardiology in collaboration with the American College ... released consensus guidelines,outlining a stepwise approach for ... bleeding among patients using nonsteroidal,anti-inflammatory drugs (NSAIDs) ...
... Oct. 6 Genaera,Corporation (Nasdaq: GENR ) today ... trodusquemine (MSI-1436), Genaera,s lead drug candidate,for the treatment of ... of PTP1B, a validated molecular target that controls the ... glucose and decrease,appetite. In the study, MSI-1436 was found ...
Cached Medicine Technology:Consensus Document Outlines Practical Steps for Reducing Gastrointestinal Risks of Antiplatelet and NSAID Use 2Consensus Document Outlines Practical Steps for Reducing Gastrointestinal Risks of Antiplatelet and NSAID Use 3Consensus Document Outlines Practical Steps for Reducing Gastrointestinal Risks of Antiplatelet and NSAID Use 4Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 2Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 3Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 4(Date:5/26/2013)... Raton, FL (PRWEB) May 26, 2013 ... Carnival Cruise Lines, the overwhelming majority of cruises go ... vacationers with enjoyable and luxurious experiences each year. Across ... ski boats to fishing boats, to yachts to cruise ... series In View hosted by Larry King ...
(Date:5/26/2013)... (PRWEB) May 26, 2013 In the five ... in China has been growing at an average annualized ... steadily due to rises in poultry prices as well as ... in people's diets as a healthier alternative to other meats. ... in China, much lower than the world average. And although ...
(Date:5/25/2013)... Today, Zane Benefits, Inc. published a ... Benefits, which provides comprehensive and flexible alternatives to traditional ... defined contribution plans and HRAs . , ... open enrollment of the Health Insurance Marketplaces is right ... "Choice, Competition and Clout for States." But which ...
(Date:5/25/2013)... MA (PRWEB) May 25, 2013 Imagine running ... -- the energy loss, hot air and wasted energy! If ... house fan, a fireplace or clothes dryer, that may be ... Drafts from these often overlooked holes waste energy in the ... of heating and cooling loss in the home. , Drafts ...
(Date:5/25/2013)... Dr. Leslie Gerstman announced today ... lift skin on the neck, on the brow and under ... Aesthetics. , Ultherapy is a non-surgical procedure for the face ... to lift the skin over time. The use of FDA-cleared ... and then treat the deepest support layers of the skin ...
Breaking Medicine News(10 mins):Health News:The In View Series Announces Plans for a New Series About Boating 2Health News:Poultry Farming Industry in China Industry Research Report – Now Available from IBISWorld 2Health News:Poultry Farming Industry in China Industry Research Report – Now Available from IBISWorld 3Health News:Zane Benefits Publishes New Information on the Health Insurance Marketplaces 2Health News:Zane Benefits Publishes New Information on the Health Insurance Marketplaces 3Health News:How To Stop Drafts and Save On Home Energy Bills This Summer - New Draft Stoppers Now Available From Battic Door Energy Conservation 2Health News:How To Stop Drafts and Save On Home Energy Bills This Summer - New Draft Stoppers Now Available From Battic Door Energy Conservation 3Health News:How To Stop Drafts and Save On Home Energy Bills This Summer - New Draft Stoppers Now Available From Battic Door Energy Conservation 4Health News:Dr. Leslie Gerstman Is Now Offering the Non-surgical Facelifting Procedure – Ultherapy – in NYC and NJ 2... for Patient Safety Legislation Essential to Reduce ... ST. PAUL, Minn., Feb. 25 The ... be addressed with legislation,advanced by the Minnesota ... will champion "Staffing For Patient Safety" legislation,that ...
... SAMHSA as First Therapeutic Community,Program in the National ... YORK, Feb. 25 The Phoenix Academy,Therapeutic Community ... first,evidence-based therapeutic community program for adolescents to be ... Practices (NREPP),created by United States Department of Health ...
... acquisition consisting of: - 7 properties acquired, in Q4 ... $485 million - 3,properties in 2009 for $180 million - ... in financing for the 16 properties closing in 2008 already, ... office space to NHP, portfolio - Provides tenant and asset ...
... wear Prada. They do Pilates.,They primp and pluck. But ... big event -- also take advantage of high-tech last-minute ... Dr. Cameron Rokhsar, a Board-Certified Dermatologic,Surgeon who has worked ... in his Upper East Side NY practice, explains the ...
... studies in the review challenges the finding , , MONDAY, Feb. ... provide a benefit over drug therapy even if it,s done ... studies claims. , However, that finding was immediately challenged by ... , "What we found is that putting all these studies ...
... Omnicell, Inc.,(Nasdaq: OMCL ), a leading provider of ... Board of Directors has approved the,repurchase of an aggregate ... over,the next 12 months. The Company,s Board of Directors ... of the Company,s financial position and,investment alternatives. The Company ...
Cached Medicine News:Health News:Minnesota Registered Nurses Promote Law to Improve Patient Care and Address Health Care Costs 2Health News:Minnesota Registered Nurses Promote Law to Improve Patient Care and Address Health Care Costs 3Health News:Minnesota Registered Nurses Promote Law to Improve Patient Care and Address Health Care Costs 4Health News:Phoenix Academy's Therapeutic Community Model Is First to be Federally Recognized as Evidence-Based 2Health News:Nationwide Health Properties and Pacific Medical Buildings Join Forces in up to $2 Billion, Multi-Year Transaction 2Health News:Nationwide Health Properties and Pacific Medical Buildings Join Forces in up to $2 Billion, Multi-Year Transaction 3Health News:Nationwide Health Properties and Pacific Medical Buildings Join Forces in up to $2 Billion, Multi-Year Transaction 4Health News:Nationwide Health Properties and Pacific Medical Buildings Join Forces in up to $2 Billion, Multi-Year Transaction 5Health News:Nationwide Health Properties and Pacific Medical Buildings Join Forces in up to $2 Billion, Multi-Year Transaction 6Health News:Nationwide Health Properties and Pacific Medical Buildings Join Forces in up to $2 Billion, Multi-Year Transaction 7Health News:Nationwide Health Properties and Pacific Medical Buildings Join Forces in up to $2 Billion, Multi-Year Transaction 8Health News:Oscar Makeover CHEAT Secrets of the Stars Revealed 2Health News:Doing Angioplasty Long After Heart Attack Still Worth It, Analysis Shows 2Health News:Omnicell Announces Common Stock Repurchase Program; Reaffirms Earnings Forecast 2Health News:Omnicell Announces Common Stock Repurchase Program; Reaffirms Earnings Forecast 3The APR Hip System offers a complete line of stems to precisely match patients' anatomic needs and address surgeon preferences....
The Perfecta PDA components provide the design and material choice imperative in today's cost conscious medical climate....
The proximally modular S-ROM Total Hip System provides custom capability at non-custom prices and is competitive with conventional porous coated systems....
The proximally modular S-ROM Total Hip System provides custom capability at non-custom prices and is competitive with conventional porous coated systems....
Medicine Products:Biology NavigationMedical Navigation